Cisplatin‐resistant HeLa Cells Are Resistant to Apoptosis via p53‐dependent and ‐independent Pathways
- 1 December 1999
- journal article
- research article
- Published by Wiley in Japanese Journal of Cancer Research
- Vol. 90 (12) , 1373-1379
- https://doi.org/10.1111/j.1349-7006.1999.tb00722.x
Abstract
Since HeLa cells possess very little functional p53 activity, they could be originally resistant to genotoxic stress‐induced apoptosis. Therefore, it is likely that the drug‐resistant cells derived from HeLa cells are more resistant to apoptosis. The aim of this study was to determine whether cisplatin‐resistant cells derived from HeLa cells have an apoptosis‐resistant phenotype. A cisplatin‐resistant cell subline, HeLa/CDDP cells, showed a 19‐fold resistance to cisplatin compared with the parent cells. The subline showed a collateral sensitivity to paclitaxel. An equitoxic dose (IC50) of cisplatin produced DNA fragmentation in HeLa cells but not in HeLa/CDDP cells. Transfection of wild‐type p53gene enhanced the cytotoxicity of cisplatin and cisplatin‐induced apoptosis in HeLa cells but not in HeLa/CDDP cells, although it caused p53 overexpression in both cell lines. The expression of caspase 1 (interleukin‐1β‐converting enzyme, ICE) mRNA and the overexpression of bax protein were observed only in HeLa cells. Paclitaxel‐induced DNA fragmentation appeared less in HeLa/CDDP cells than in HeLa cells. p53gene transfection did not affect the extent of DNA fragmentation in either cell line, suggesting that paclitaxel may induce p53‐independent apoptosis. These findings suggest that HeLa/CDDP cells may have an acquired phenotype that is resistant to p53‐dependent and ‐independent apoptosis.Keywords
This publication has 40 references indexed in Scilit:
- Inactivation of p53 in a Human Ovarian Cancer Cell Line Increases the Sensitivity to Paclitaxel by Inducing G2/M Arrest and ApoptosisExperimental Cell Research, 1998
- Deficient Apoptotic Process in Cisplatin-Resistant L1210 Cells Cannot Account for the Cellular Response to Various Drug TreatmentsBiochemical and Biophysical Research Communications, 1997
- Identification of p53 genetic suppressor elements which confer resistance to cisplatinOncogene, 1997
- Cisplatin-induced apoptosis andp53 gene status in a cisplatin-resistant human ovarian carcinoma cell lineInternational Journal of Cancer, 1996
- Cisplatin Resistance in a Murine Leukemia Cell Line Is Associated with a Defective Apoptotic ProcessExperimental Cell Research, 1995
- Synergistic Enhancement of Cisplatin Cytotoxicity by SN‐38, an Active Metabolite of CPT‐11, for Cisplatin‐resistant HeLa CellsJapanese Journal of Cancer Research, 1994
- Apoptosis Biochemical events and relevance to cancer chemotherapyFEBS Letters, 1992
- p53, guardian of the genomeNature, 1992
- Analysis of Events Associated With Cell Cycle Arrest at G2 Phase and Cell Death Induced by CisplatinJNCI Journal of the National Cancer Institute, 1990
- Analysis of human p53 proteins and mRNA levels in normal and transformed cellsEuropean Journal of Biochemistry, 1986